DE3584353D1 - Transformation von hefe des genus pichia. - Google Patents

Transformation von hefe des genus pichia.

Info

Publication number
DE3584353D1
DE3584353D1 DE8585113733T DE3584353T DE3584353D1 DE 3584353 D1 DE3584353 D1 DE 3584353D1 DE 8585113733 T DE8585113733 T DE 8585113733T DE 3584353 T DE3584353 T DE 3584353T DE 3584353 D1 DE3584353 D1 DE 3584353D1
Authority
DE
Germany
Prior art keywords
genus pichia
year
transformation
yeast strains
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8585113733T
Other languages
English (en)
Inventor
David Womack Stroman
James Michael Cregg
George T Sperl
Michael Miller Harpold
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RESEARCH CORPORATION TECHNOLOGIES, INC. (N.D.GES.D
Original Assignee
Phillips Petroleum Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phillips Petroleum Co filed Critical Phillips Petroleum Co
Application granted granted Critical
Publication of DE3584353D1 publication Critical patent/DE3584353D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
DE8585113733T 1984-10-30 1985-10-29 Transformation von hefe des genus pichia. Expired - Lifetime DE3584353D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/666,579 US4879231A (en) 1984-10-30 1984-10-30 Transformation of yeasts of the genus pichia

Publications (1)

Publication Number Publication Date
DE3584353D1 true DE3584353D1 (de) 1991-11-14

Family

ID=24674609

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8585113733T Expired - Lifetime DE3584353D1 (de) 1984-10-30 1985-10-29 Transformation von hefe des genus pichia.

Country Status (18)

Country Link
US (1) US4879231A (de)
EP (1) EP0183070B1 (de)
JP (1) JPH0681593B2 (de)
AT (1) ATE68204T1 (de)
AU (1) AU572353B2 (de)
CA (1) CA1297438C (de)
DE (1) DE3584353D1 (de)
DK (1) DK496485A (de)
ES (1) ES8609464A1 (de)
FI (1) FI94428C (de)
GR (1) GR852609B (de)
IE (1) IE58217B1 (de)
IL (1) IL76763A (de)
MX (1) MX430A (de)
NO (1) NO178975C (de)
PT (1) PT81402B (de)
SG (1) SG43092G (de)
ZA (1) ZA858180B (de)

Families Citing this family (437)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4885242A (en) * 1984-10-30 1989-12-05 Phillips Petroleum Company Genes from pichia histidine pathway and uses thereof
US4855231A (en) * 1984-10-30 1989-08-08 Phillips Petroleum Company Regulatory region for heterologous gene expression in yeast
US4818700A (en) * 1985-10-25 1989-04-04 Phillips Petroleum Company Pichia pastoris argininosuccinate lyase gene and uses thereof
US4882279A (en) * 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
US4895800A (en) * 1985-11-26 1990-01-23 Phillips Petroleum Company Yeast production of hepatitis B surface antigen
ZA872534B (en) * 1986-05-08 1987-11-25 Phillips Petroleum Co Yeast production of streptokinase
US5258287A (en) * 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
IL89989A0 (en) * 1988-04-25 1989-12-15 Phillips Petroleum Co Expression of human interleukin-2 in methylotrophic yeasts
IL89991A0 (en) * 1988-04-25 1989-12-15 Phillips Petroleum Co Expression of hepatitis b pres2 protein in methylotrophic yeasts
US5204252A (en) * 1989-02-08 1993-04-20 Henkel Research Corporation Candida tropicalis transformation system
WO1990009434A1 (en) * 1989-02-13 1990-08-23 The Salk Institute Biotechnology/Industrial Associates, Inc. Production of superoxide dismutase in pichia pastoris yeast cells
US5254466A (en) * 1989-11-06 1993-10-19 Henkel Research Corporation Site-specific modification of the candida tropicals genome
US5612198A (en) * 1990-09-04 1997-03-18 The Salk Institute Production of insulin-like growth factor-1 in methylotrophic yeast cells
WO1992013951A1 (en) * 1991-02-04 1992-08-20 The Salk Institute Biotechnology/Industrial Associates, Inc. Production of human serum albumin in methylotrophic yeast cells
CA2105064A1 (en) * 1991-04-01 1992-10-02 Martin Anthony Gleeson Genes which influence pichia proteolytic activity, and uses therefor
US6872550B1 (en) * 1991-07-11 2005-03-29 Baxter Vaccine Ag Immunogenic formulation of OspC antigen vaccines for the prevention and treatment of lyme disease and recombinant methods for the preparation of such antigens
US5665600A (en) * 1991-09-18 1997-09-09 Research Corporation Technologies, Inc. Pichia pastoris linear plasmids and DNA fragments thereof
AU664469B2 (en) 1992-06-03 1995-11-16 Genentech Inc. Tissue plasminogen activator glycosylation variants with improved therapeutic properties
BR9405944A (pt) * 1993-03-03 1996-02-06 Du Pont Glicolato oxidase enzimaticamente ativa processo para produzi-la levedura metilotrofica transformada picchia pastoris msp 10 picchia pstoris msp12 sequência de ácido nucléico e plasmideo pmp1
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US5708142A (en) 1994-05-27 1998-01-13 Genentech, Inc. Tumor necrosis factor receptor-associated factors
CA2202351A1 (en) * 1994-10-18 1996-04-25 George Phillip Vlasuk Nematode-extracted serine protease inhibitors and anticoagulant proteins
US5863894A (en) * 1995-06-05 1999-01-26 Corvas International, Inc. Nematode-extracted anticoagulant protein
US5866543A (en) * 1995-06-05 1999-02-02 Corvas International, Inc. Nematode-extracted anticoagulant protein
US5866542A (en) * 1994-10-18 1999-02-02 Corvas International, Inc. Nematode-extracted anticoagulant protein
US5872098A (en) * 1995-06-05 1999-02-16 Corvas International, Inc. Nematode-extracted anticoagulant protein
US5945275A (en) * 1994-10-18 1999-08-31 Corvas International, Inc. Nematode-extracted anticoagulant protein
EP0788546B9 (de) * 1994-10-18 2007-06-13 Dendreon Corporation Aus nematoden extrahierte serinprotease-inhibitoren und die koagulation hemmende proteine
AU710696C (en) 1995-09-08 2002-10-24 Genentech Inc. VEGF-related protein
JP2000500015A (ja) * 1995-11-09 2000-01-11 ザイモジェネティクス，インコーポレイティド メチロトロープ性酵母におけるｇａｄ６５の生成
US5955349A (en) * 1996-08-26 1999-09-21 Zymogenetics, Inc. Compositions and methods for producing heterologous polypeptides in Pichia methanolica
US5716808A (en) * 1995-11-09 1998-02-10 Zymogenetics, Inc. Genetic engineering of pichia methanolica
IL125073A0 (en) 1996-01-08 1999-01-26 Genentech Inc Wsx receptor and ligands
US5736383A (en) * 1996-08-26 1998-04-07 Zymogenetics, Inc. Preparation of Pichia methanolica auxotrophic mutants
US5854039A (en) * 1996-07-17 1998-12-29 Zymogenetics, Inc. Transformation of pichia methanolica
US6159462A (en) * 1996-08-16 2000-12-12 Genentech, Inc. Uses of Wnt polypeptides
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
MX9605082A (es) 1996-10-24 1998-04-30 Univ Autonoma De Nuevo Leon Levaduras metilotroficas modificadas geneticamente para la produccion y secrecion de hormona de crecimiento humano.
JP3394540B2 (ja) 1997-01-31 2003-04-07 ジェネンテク・インコーポレイテッド Ｏ−フコシルトランスフェラーゼ
US6100076A (en) 1997-01-31 2000-08-08 Genentech, Inc. O-fucosyltransferase
EP0973804B1 (de) 1997-04-07 2006-12-27 Genentech, Inc. Anti-vefg antibodies
EP3260468A1 (de) 1997-04-07 2017-12-27 Genentech, Inc. Anti-vegf-antikörper
US6265186B1 (en) 1997-04-11 2001-07-24 Dsm N.V. Yeast cells comprising at least two copies of a desired gene integrated into the chromosomal genome at more than one non-ribosomal RNA encoding domain, particularly with Kluyveromyces
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
ATE406441T1 (de) 1997-10-29 2008-09-15 Genentech Inc Verwendung des wnt-1 induzierten sekretierten polypeptids wisp-1
EP2033970A3 (de) 1997-10-29 2009-06-17 Genentech, Inc. WNT-1-induzierbare Gene
EP2050762A3 (de) 1998-03-10 2009-07-08 Genentech, Inc. Neue Polypeptide und für diese kodierende Nukleinsäuren
EP3112468A1 (de) 1998-05-15 2017-01-04 Genentech, Inc. Il-17-homologe polypeptide und therapeutische verwendung davon
EP1865061A3 (de) 1998-05-15 2007-12-19 Genentech, Inc. IL-17-homologe Polypeptide und ihre therapeutische Verwendung
EP2333069A3 (de) 1998-05-15 2011-09-14 Genentech, Inc. Therapeutische verwendungen von il-17 homologe polypeptide
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
US6316245B1 (en) * 1998-09-16 2001-11-13 Biongene Co., Ltd. Mutant cells of Pichia
EP1950300A3 (de) 1998-11-18 2011-03-23 Genentech, Inc. Antikörpervarianten mit höherer Bindungsaffinität im Vergleich zu verwandten Antikörpern
EP2075335A3 (de) 1998-12-22 2009-09-30 Genentech, Inc. Verfahren und Zusammensetzungen zur Hemmung des neoplastischen Zellenwachstums
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US6720174B1 (en) 1999-01-28 2004-04-13 Novozymes A/S Phytases
EP1956030B1 (de) 1999-06-15 2009-11-11 Genentech, Inc. Sekretierte und Transmembran-Polypeptide sowie Nukleinsäuren zu deren Kodierung
EP1189641B1 (de) 1999-06-25 2009-07-29 Genentech, Inc. Humanisierte anti-erbb2 antikörper und behandlung mit anti-erbb2 antikörper
AU7878900A (en) * 1999-10-15 2001-04-30 Heska Corporation Method for production and use of mite group 1 proteins
EP2228446A1 (de) 1999-12-01 2010-09-15 Genentech, Inc. Sekretierte und transmembrane Polypeptide, sowie dafür codierende Nukleinsäuren
EP2290081A3 (de) 1999-12-23 2012-08-01 Genentech, Inc. IL-17-homologe Polypeptide und ihre therapeutische Verwendung
WO2001077351A1 (en) * 2000-04-07 2001-10-18 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Vectors and methods for dual protein expression in pichia pastoris and escherichia coli
ES2528794T3 (es) 2000-04-11 2015-02-12 Genentech, Inc. Anticuerpos multivalentes y usos de los mismos
EP2077276A1 (de) 2000-06-23 2009-07-08 Genentech, Inc. Zusammensetzungen und Verfahren zur Diagnose und Behandlung von Erkrankungen in Verbindung mit Angiogenese
EP2042597B1 (de) 2000-06-23 2014-05-07 Genentech, Inc. Zusammensetzungen und Verfahren zur Diagnose und Behandlung von Erkrankungen in Verbindung mit Angiogenese
US8697394B2 (en) * 2000-06-28 2014-04-15 Glycofi, Inc. Production of modified glycoproteins having multiple antennary structures
US7625756B2 (en) 2000-06-28 2009-12-01 GycoFi, Inc. Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells
US7863020B2 (en) 2000-06-28 2011-01-04 Glycofi, Inc. Production of sialylated N-glycans in lower eukaryotes
US7598055B2 (en) * 2000-06-28 2009-10-06 Glycofi, Inc. N-acetylglucosaminyltransferase III expression in lower eukaryotes
KR100787073B1 (ko) * 2000-06-28 2007-12-21 글리코파이, 인크. 변형된 당단백질의 제조방법
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US6803225B2 (en) 2000-06-30 2004-10-12 Flanders Interuniversity Institute For Biotechnology Protein glycosylation modification in Pichia pastoris
US7009045B2 (en) * 2000-07-14 2006-03-07 Archer-Daniels-Midland Company Transformation systems for flavinogenic yeast
ATE415978T1 (de) 2000-07-27 2008-12-15 Genentech Inc Sequentielle verabreichung von cpt-11 und apo-2l polypeptid
ATE412009T1 (de) 2000-08-24 2008-11-15 Genentech Inc Methode zur inhibierung von il-22 induziertem pap1
EP1944317A3 (de) 2000-09-01 2008-09-17 Genentech, Inc. Sekretierte und Transmembran-Polypeptide sowie Nukleinsäure zu deren Kodierung
US6673580B2 (en) 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
US7265208B2 (en) 2001-05-01 2007-09-04 The Regents Of The University Of California Fusion molecules and treatment of IgE-mediated allergic diseases
WO2002088317A2 (en) 2001-05-01 2002-11-07 The Regents Of The University Of California Fusion molecules and methods for treatment of immune diseases
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
EP1992643A3 (de) 2001-06-20 2008-12-10 Genentech, Inc. Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
CN1575338B (zh) 2001-08-29 2012-05-16 杰南技术公司 具有促细胞分裂活性的Bv8的核酸和多肽
WO2003024392A2 (en) 2001-09-18 2003-03-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2003088808A2 (en) 2002-04-16 2003-10-30 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1575571A4 (de) 2002-01-02 2008-06-25 Genentech Inc Zusammensetzungen und verfahren zur diagnose und behandlung eines tumors
CA2476518A1 (en) 2002-02-22 2003-09-04 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP2305710A3 (de) 2002-06-03 2013-05-29 Genentech, Inc. Synthetische Antikörperphagenbibliotheken
JP2005528905A (ja) 2002-06-07 2005-09-29 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療のための組成物と方法
US7252933B2 (en) 2002-06-26 2007-08-07 Flanders Interuniversity Institute For Biotechnology Protein glycosylation modification in methylotrophic yeast
PT1585966E (pt) 2002-07-15 2012-02-20 Hoffmann La Roche Tratamento de cancro com o anticorpo anti-erbb2 rhumab 2c4
JP5401001B2 (ja) 2002-09-11 2014-01-29 ジェネンテック， インコーポレイテッド 免疫関連疾患の治療のための新規組成物と方法
WO2004024072A2 (en) 2002-09-11 2004-03-25 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
ES2629602T5 (es) 2002-09-11 2021-06-08 Genentech Inc Purificación de proteínas
EP2444409A2 (de) 2002-09-16 2012-04-25 Genentech, Inc. Zusammensetzungen und Verfahren zur Behandlung von Immunerkrankungen
EP1585482A4 (de) 2002-09-25 2009-09-09 Genentech Inc Neue zusammensetzungen und verfahren zur behandlung von psoriasis
EP2322202A3 (de) 2002-10-29 2011-07-27 Genentech, Inc. Gestaltungen und methoden für die behandlung von Immune verwandte Krankheiten
CA2503748A1 (en) 2002-11-08 2004-05-27 Genentech, Inc. Compositions and methods for the treatment of natural killer cell related diseases
WO2004047728A2 (en) 2002-11-26 2004-06-10 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
DE60332957D1 (de) 2002-12-16 2010-07-22 Genentech Inc Immunoglobulinvarianten und deren verwendungen
ATE494367T1 (de) * 2002-12-18 2011-01-15 Hoffmann La Roche Rekombinante desoxyribonuclease i aus rinder- pankreas mit hoher spezifischer aktivität
ATE387494T1 (de) * 2002-12-20 2008-03-15 Hoffmann La Roche Hitzelabile desoxyribonuklease i-varianten
CA2513113A1 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
US7332299B2 (en) 2003-02-20 2008-02-19 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes
JP4912144B2 (ja) 2003-03-12 2012-04-11 ジェネンテック， インコーポレイテッド 造血促進のためのｂｖ８及び／又はｅｇ−ｖｅｇｆの使用
EP1460425A1 (de) * 2003-03-17 2004-09-22 Boehringer Mannheim Gmbh Entglykosilierte Enzymen für Konjugaten
BRPI0403964B8 (pt) 2003-04-04 2021-05-25 Genentech Inc formulações líquidas estáveis, artigo manufaturado e uso dessas formulações para o tratamento de disfunção mediada por ige
MXPA05012723A (es) 2003-05-30 2006-02-08 Genentech Inc Tratamiento con anticuerpos anti-vgf.
BRPI0411132B8 (pt) 2003-06-12 2021-05-25 Lilly Co Eli protéina de fusão heteróloga e seus usos
SI1641822T1 (sl) 2003-07-08 2013-08-30 Genentech, Inc. IL-17 A/F heterologni polipeptidi in njihove terapevtske uporabe
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US7354734B2 (en) * 2003-08-25 2008-04-08 Funzyme Biotechnologies Sa Fungal proteins and nucleic acids encoding same
EP1689432B1 (de) 2003-11-17 2009-12-30 Genentech, Inc. Zusammensetzungen und verfahren zur behandlung von tumoren hämatopoetischen ursprungs
CA2486195C (en) * 2003-12-05 2012-03-06 Stephan Glaser Recombinantly expressed carboxypeptidase b and purification thereof
DK1704166T3 (en) 2004-01-07 2015-06-01 Novartis Vaccines & Diagnostic M-CSF-SPECIFIC MONOCLONAL ANTIBODY AND APPLICATIONS THEREOF
CN102250861A (zh) 2004-02-13 2011-11-23 诺维信公司 蛋白酶变体
AU2005229457B2 (en) 2004-03-30 2010-11-25 Glaxo Group Limited Immunoglobulins
US7794713B2 (en) 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
US20150017671A1 (en) 2004-04-16 2015-01-15 Yaping Shou Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
ZA200701183B (en) 2004-07-20 2008-05-28 Genentech Inc Inhibitors of angiopoietin-like 4 protein, combinations, an their use
ES2402277T3 (es) 2004-11-10 2013-04-30 Diadexus, Inc. Composiciones de anticuerpo contra Ovr110 y procedimientos de uso
US7964195B2 (en) 2005-01-07 2011-06-21 Diadexus, Inc. Ovr110 antibody compositions and methods of use
US7858843B2 (en) 2005-06-06 2010-12-28 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
AU2006280321A1 (en) 2005-08-15 2007-02-22 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
US9056921B2 (en) 2005-08-16 2015-06-16 Novo Nordisk A/S Method for making mature insulin polypeptides
ES2370657T3 (es) * 2005-09-14 2011-12-21 Sanofi-Aventis Deutschland Gmbh Escisión de precursores de insulinas mediante una variante de tripsina.
UA96139C2 (uk) 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
CN101360826B (zh) 2005-11-18 2014-04-30 格兰马克药品股份有限公司 抗α2整联蛋白抗体及它们的用途
AU2006335053A1 (en) 2005-11-21 2007-07-19 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
CA2638821A1 (en) 2006-02-17 2007-10-11 Genentech, Inc. Gene disruptons, compositions and methods relating thereto
EP2389948A1 (de) 2006-03-23 2011-11-30 Novartis AG Antitumorzellenantigen-Antikörper-Therapeutika
NZ611859A (en) 2006-04-05 2014-12-24 Abbvie Biotechnology Ltd Antibody purification
EP2614839A3 (de) 2006-04-05 2015-01-28 Genentech, Inc. Verfahren zur Verwendung von BOC/CDO zur Modulation der Hedgehog-Signalisierung
EP2082645A1 (de) 2006-04-19 2009-07-29 Genentech, Inc. Neuartige Genunterbrechungen, dazugehörige Zusammensetzungen und Verfahren in Zusammenhang damit
CA2650730A1 (en) 2006-04-27 2007-11-08 Pikamab, Inc. Methods and compositions for antibody therapy
AU2007249160B2 (en) 2006-05-15 2013-09-12 I2 Pharmaceuticals, Inc. Neutralizing antibodies to influenza viruses
US7862812B2 (en) 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
EP2044111B1 (de) 2006-06-21 2014-08-13 MUSC Foundation For Research Development Targeting des komplement-faktors h zur krankheitsbehandlung
RU2499001C2 (ru) 2006-06-30 2013-11-20 Ново Нордиск А/С Антитела к nkg2a и их применения
GEP20125612B (en) 2006-08-18 2012-08-27 Novartis Ag Prlr-specific antibody and usage thereof
WO2008037735A1 (en) 2006-09-27 2008-04-03 Novo Nordisk A/S Method for making maturated insulin polypeptides
JP5795833B2 (ja) 2006-10-27 2015-10-14 エルパス・インコーポレイテッドＬｐａｔｈ， Ｉｎｃ． スフィンゴシン−１−リン酸と結合させるための組成物および方法
WO2008055072A2 (en) 2006-10-27 2008-05-08 Lpath, Inc. Compositions and methods for treating ocular diseases and conditions
WO2008140477A2 (en) 2006-11-02 2008-11-20 Capon Daniel J Hybrid immunoglobulins with moving parts
MX2009004757A (es) 2006-11-14 2009-05-21 Genentech Inc Moduladores de regeneracion neuronal.
AU2007325838B2 (en) 2006-11-22 2013-09-19 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
JP5391073B2 (ja) 2006-11-27 2014-01-15 ディアデクサス インコーポレーテッド Ｏｖｒ１１０抗体組成物および使用方法
US8288110B2 (en) * 2006-12-04 2012-10-16 Perkinelmer Health Sciences, Inc. Biomarkers for detecting cancer
WO2008070780A1 (en) 2006-12-07 2008-06-12 Novartis Ag Antagonist antibodies against ephb3
ES2426158T3 (es) 2007-01-22 2013-10-21 Genentech, Inc. Precipitación con polielectrolito y purificación de anticuerpos
US20100144599A1 (en) 2007-02-02 2010-06-10 Bristol-Myers Squibb Company Vegf pathway blockade
US7875431B2 (en) 2007-02-22 2011-01-25 Genentech, Inc. Methods for detecting inflammatory bowel disease
WO2008120107A2 (en) 2007-04-03 2008-10-09 Oxyrane (Uk) Limited Glycosylation of molecules
US9163091B2 (en) 2007-05-30 2015-10-20 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
ES2585702T3 (es) 2007-05-30 2016-10-07 Lpath, Inc Composiciones y métodos para la unión al ácido lisofosfatídico
KR101572700B1 (ko) 2007-06-07 2015-11-30 제넨테크, 인크. 보체-관련 장애의 예방 및 치료를 위한 Ｃ３ｂ 항체 및 방법
SI3597659T1 (sl) 2007-07-09 2023-04-28 Genentech, Inc. Preprečevanje redukcije disulfidne vezi med rekombinantno proizvodnjo polipeptidov
TW200918089A (en) 2007-07-16 2009-05-01 Genentech Inc Humanized anti-CD79b antibodies and immunoconjugates and methods of use
JP5469600B2 (ja) 2007-07-16 2014-04-16 ジェネンテック， インコーポレイテッド 抗ＣＤ７９ｂ抗体及びイムノコンジュゲートとその使用方法
CN101361968B (zh) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 白介素-22在治疗脂肪肝中的应用
US8361465B2 (en) 2007-10-26 2013-01-29 Lpath, Inc. Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
RS53850B2 (sr) 2007-10-30 2018-07-31 Genentech Inc Pročišćavanje antitela hromatografijom izmene katjona
EP2209807A1 (de) 2007-11-08 2010-07-28 Genentech, Inc. Anti-faktor-b-antikörper und ihre verwendungen
KR20100097691A (ko) 2007-11-12 2010-09-03 테라클론 사이언시스, 아이엔씨. 인플루엔자의 치료 및 진단을 위한 조성물 및 방법
AR069501A1 (es) 2007-11-30 2010-01-27 Genentech Inc Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
AR070141A1 (es) 2008-01-23 2010-03-17 Glenmark Pharmaceuticals Sa Anticuerpos humanizados especificos para el factor von willebrand
EP2247619A1 (de) 2008-01-24 2010-11-10 Novo Nordisk A/S Humanisierter monoklonaler anti-human-nkg2a-antikörper
SI2657253T1 (sl) 2008-01-31 2017-10-30 Genentech, Inc. Protitelesa proti CD79b in imunokonjugati in postopki za uporabo
WO2009114093A2 (en) * 2008-03-03 2009-09-17 Abbott Laboratories Methods for transforming yeast
AU2009223688B2 (en) 2008-03-10 2014-12-11 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of cytomegalovirus infections
JP2011516423A (ja) 2008-03-28 2011-05-26 シー レーン バイオテクノロジーズ， エルエルシー ウイルス抗原に対する中和分子
SG10201402815VA (en) 2008-04-09 2014-09-26 Genentech Inc Novel compositions and methods for the treatment of immune related diseases
DK2280996T3 (en) 2008-05-06 2016-12-19 Genentech Inc Affinity matured CRIg VARIANTS
CA2726804C (en) 2008-06-02 2021-12-28 Dana-Farber Cancer Institute, Inc. Xbp1, cd138, and cs1 peptides
HUE047316T2 (hu) 2008-08-14 2020-04-28 Genentech Inc Eljárások szennyezés eltávolítására indigén fehérjekiszorításos ioncserés membrán kromatográfia alkalmazásával
US8937046B2 (en) 2008-09-22 2015-01-20 The Regents Of The University Of Colorado, A Body Corporate Modulating the alternative complement pathway
CA2932207A1 (en) 2008-10-20 2010-12-09 Abbvie Inc. Isolation and purification of antibodies using protein a affinity chromatography
AU2009308293B2 (en) 2008-10-22 2015-02-05 Genentech, Inc. Modulation of axon degeneration
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
JP5775458B2 (ja) 2008-11-06 2015-09-09 グレンマーク ファーマシューティカルズ， エセ．アー． 抗α２インテグリン抗体を使用する処置
UY32341A (es) 2008-12-19 2010-07-30 Glaxo Group Ltd Proteínas de unión antígeno novedosas
WO2010078376A2 (en) 2008-12-30 2010-07-08 Ventana Medical Systems, Inc. Fc-specific polymer-conjugated antibodies and their diagnostic use
CN116925238A (zh) 2009-02-03 2023-10-24 阿穆尼克斯制药公司 延伸重组多肽和包含该延伸重组多肽的组合物
SI3260136T1 (sl) 2009-03-17 2021-05-31 Theraclone Sciences, Inc. Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
AU2010236787A1 (en) 2009-04-01 2011-11-10 Genentech, Inc. Anti-FcRH5 antibodies and immunoconjugates and methods of use
WO2010118243A2 (en) 2009-04-08 2010-10-14 Genentech, Inc. Use of il-27 antagonists to treat lupus
CA2759506A1 (en) 2009-04-23 2010-10-28 Theraclone Sciences, Inc. Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
AU2010249787A1 (en) 2009-05-20 2011-12-22 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
CA2764108A1 (en) 2009-06-08 2010-12-16 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
EP3278813A1 (de) 2009-06-08 2018-02-07 Amunix Operating Inc. Wachstumshormonpolypeptide sowie verfahren zur herstellung und verwendung davon
WO2011008959A1 (en) 2009-07-15 2011-01-20 Abbott Laboratories Enhancement of cellular production through mechanotransduction
NZ597531A (en) 2009-07-31 2014-05-30 Genentech Inc Inhibition of tumor metastasis using bv8- or g-csf-antagonists
US9428548B2 (en) 2009-09-01 2016-08-30 Genentech, Inc. Enhanced protein purification through a modified protein A elution
US9321823B2 (en) 2009-09-02 2016-04-26 Genentech, Inc. Mutant smoothened and methods of using the same
US9885711B2 (en) 2009-09-25 2018-02-06 Xoma Technology Ltd. Screening methods
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
WO2011039634A2 (en) 2009-09-29 2011-04-07 Universiteit Gent Hydrolysis of mannose-1-phospho-6-mannose linkage to phospho-6-mannose
US8535912B2 (en) 2009-10-15 2013-09-17 Genentech, Inc. Chimeric fibroblast growth factors with altered receptor specificity
RS60577B1 (sr) 2009-10-20 2020-08-31 Abbvie Inc Izolacija i prečišćavanje anti-il-13 antitela upotrebom protein a afinitetne hromatografije
CN104043126A (zh) 2009-10-22 2014-09-17 霍夫曼-拉罗奇有限公司 轴突变性的调节
BR112012009409A2 (pt) 2009-10-22 2017-02-21 Genentech Inc método de identificação de uma substância inibidora, molécula antagonista, ácido nucleico isolado, vetor, célula hospedeira, método para fabricar a molécula, composição, artigo de fabricação, método de inibição de uma atividade biológica, método de tratamento de uma condição patológica, método para detectar msp em uma amostra e método para detectar hepsina em uma amostra
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
US20110098862A1 (en) 2009-10-27 2011-04-28 ExxonMobil Research Engineering Company Law Department Multi-stage processes and control thereof
CN102612374A (zh) 2009-11-12 2012-07-25 霍夫曼-拉罗奇有限公司 提升树突棘密度的方法
EP2501805B1 (de) 2009-11-19 2019-02-20 Oxyrane UK Limited Hefe stämme die säugetier-ähnliche n-glykane produzieren
AR079217A1 (es) 2009-11-30 2012-01-04 Genentech Inc Composiciones y metodos para el diagnostico y el tratamiento de tumores
WO2011080050A2 (en) 2009-12-11 2011-07-07 Novartis Ag Binding molecules
TWI505836B (zh) 2009-12-11 2015-11-01 Genentech Inc 抗－ｖｅｇｆ－ｃ抗體及其使用方法
PL3715356T3 (pl) 2009-12-18 2024-03-11 Csl Limited Sposób oczyszczania polipeptydów
KR101989628B1 (ko) 2009-12-21 2019-06-14 제넨테크, 인크. 항체 제제
EP2515932A2 (de) 2009-12-21 2012-10-31 Centre Hospitalier Universitaire Vaudois (CHUV) Synergetische wirkung einer prolylprotease und tripeptidylproteasen
WO2011094259A2 (en) 2010-01-28 2011-08-04 Glaxo Group Limited Cd127 binding proteins
MX2012009215A (es) 2010-02-23 2012-11-23 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento de tumores.
JP5972176B2 (ja) 2010-02-23 2016-08-17 サノフイ 抗アルファ２インテグリン抗体及びそれらの使用
UA108227C2 (xx) 2010-03-03 2015-04-10 Антигензв'язуючий білок
HUE038788T2 (hu) 2010-03-31 2018-11-28 Boehringer Ingelheim Int Anti-CD40 antitestek
WO2011133931A1 (en) 2010-04-22 2011-10-27 Genentech, Inc. Use of il-27 antagonists for treating inflammatory bowel disease
MA34291B1 (fr) 2010-05-03 2013-06-01 Genentech Inc Compositions et méthodes de diagnostic et de traitement d'une tumeur
JP6050226B2 (ja) 2010-05-28 2016-12-21 ジェネンテック， インコーポレイテッド Ｌｄｈ及びｐｄｈｋ発現を下方制御することによる乳酸レベルの低下及びポリペプチド生産の増加
JP2013534515A (ja) 2010-06-01 2013-09-05 モナシュ ユニバーシティ プロセシングされていない受容体型チロシンキナーゼｃ−ＭＥＴに対する抗体
AR081556A1 (es) 2010-06-03 2012-10-03 Glaxo Group Ltd Proteinas de union al antigeno humanizadas
US20130150286A1 (en) 2010-06-25 2013-06-13 Jean-Claude Sirard Methods and pharmaceutical compositions for the treatment of respiratory tract infections
BR112013001637A2 (pt) 2010-07-22 2016-05-24 Glaxosmithkline Biolog Sa proteína ligadora de antígeno, molécula de ácido nucleico, vetor de expressão, célula hospedeira recombinante, métodos para produção de proteína ligadora de antígeno, e para detectar mage-a3 e/ou mage-a6 em tecido de humano fixado com formalina e infiltrado em parafina.
JP2013540701A (ja) 2010-08-12 2013-11-07 セラクローン サイエンシーズ， インコーポレイテッド 抗赤血球凝集素抗体組成物およびその使用方法
EP2420250A1 (de) 2010-08-13 2012-02-22 Universitätsklinikum Münster Anti-Syndecan-4-Antikörper
BR112013003279A2 (pt) 2010-08-13 2016-06-14 Genentech In “métodos para tratar uma doença, método para neutralizar ou bloquear a atividade de il-1ß e/ou il-18, anticorpo, usos de um anticorpo e usos de um anticorpo monoclonal”
WO2012027494A1 (en) 2010-08-24 2012-03-01 Regents Of The University Of Minnesota Bispecific targeting reagents
PT3556396T (pt) 2010-08-31 2022-07-04 Scripps Research Inst Anticorpos neutralizantes do vírus da imunodeficiência humana (vih)
CN102380091A (zh) 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 白介素-22在治疗病毒性肝炎中的应用
CN103797026A (zh) 2010-09-15 2014-05-14 阿利吉那科技有限公司 由木质素衍生的化合物生物生产芳香族化学品
US20120122076A1 (en) 2010-09-20 2012-05-17 Abbott Laboratories Purification of antibodies using simulated moving bed chromatography
CA2812870C (en) 2010-09-29 2020-06-09 Oxyrane Uk Limited Mannosidases capable of uncapping mannose-1-phospho-6-mannose linkages and demannosylating phosphorylated n-glycans and methods of facilitating mammalian cellular uptake of glycoproteins
BR112013007263A2 (pt) 2010-09-29 2016-06-14 Oxyrane Uk Ltd desmanosilação de n-glicanos fosforilados
WO2012047968A2 (en) 2010-10-05 2012-04-12 Genentech, Inc. Mutant smoothened and methods of using the same
CA2814023C (en) 2010-10-08 2018-01-16 Shanghai Kexin Biotech Co., Ltd. Moesin fragments and uses thereof
WO2012045279A1 (en) 2010-10-08 2012-04-12 Shanghai Kexin Biotech Co., Ltd. Moesin fragments associated with immune thrombocytopenia
JP6080763B2 (ja) 2010-10-08 2017-02-15 シャンハイ クーシン バイオテック カンパニー，リミテッド モエシンモジュレーターおよびその使用
US9345765B2 (en) 2010-10-08 2016-05-24 Shanghai Kexin Biotech Co., Ltd. Diagnostic and therapeutic uses of moesin fragments
CA2814026C (en) 2010-10-08 2017-07-11 Shanghai Kexin Biotech Co., Ltd. Moesin fragments associated with aplastic anemia
EA030436B1 (ru) 2010-11-04 2018-08-31 Бёрингер Ингельхайм Интернациональ Гмбх АНТИТЕЛА К IL-23p19 ИЛИ ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ФРАГМЕНТЫ, ИХ ПРИМЕНЕНИЕ, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ЭТИ АНТИТЕЛА, СПОСОБ ИХ ПОЛУЧЕНИЯ, ВЫДЕЛЕННЫЕ ПОЛИНУКЛЕОТИДЫ, ЭКСПРЕССИОННЫЕ ВЕКТОРЫ И КЛЕТКИ ДЛЯ ПОЛУЧЕНИЯ АНТИТЕЛ
US20130224116A1 (en) 2010-11-05 2013-08-29 TransBio Ltd. Markers of Endothelial Progenitor Cells and Uses Thereof
KR20130118899A (ko) 2010-11-05 2013-10-30 애브비 인코포레이티드 세포배양에서의 화학적으로 규명된 배지의 개발을 위한 효율적이고 효과적인 보충물 스크리닝
WO2012064619A1 (en) * 2010-11-10 2012-05-18 Merck Sharp & Dohme Corp. Pichia pastoris loci encoding enzymes in the proline biosynthetic pathway
US20140199682A1 (en) 2010-11-17 2014-07-17 Sea Lane Biotechnologies, Llc Influenza neutralizing agents
JP6147670B2 (ja) 2010-12-22 2017-06-14 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 改善された半減期を有する修飾された抗体
AU2012217867A1 (en) 2011-02-14 2013-09-05 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
WO2012122528A1 (en) 2011-03-10 2012-09-13 Hco Antibody, Inc. Bispecific three-chain antibody-like molecules
WO2012122512A1 (en) 2011-03-10 2012-09-13 Hco Antibody, Inc. Recombinant production of mixtures of single chain antibodies
EP2685968A1 (de) 2011-03-15 2014-01-22 Theraclone Sciences, Inc. Zusammensetzungen und verfahren zur therapie und diagnose von grippe
WO2012125735A1 (en) 2011-03-15 2012-09-20 Abott Laboratories An integrated approach to the isolation and purification of antibodies
TW201239355A (en) 2011-03-23 2012-10-01 Abbott Lab Methods and systems for the analysis of protein samples
CA2831732C (en) 2011-03-31 2019-12-31 Genentech, Inc. Use of a monoclonal anti-beta7 antibody for treating gastrointestinal inflammatory disorders
EP2702077A2 (de) 2011-04-27 2014-03-05 AbbVie Inc. Verfahren zur steuerung des galactosylierungsprofil von rekombinant exprimierten proteinen
CN103842383B (zh) 2011-05-16 2017-11-03 健能隆医药技术（上海）有限公司 多特异性fab融合蛋白及其使用方法
SG10201902706VA (en) 2011-06-03 2019-04-29 Xoma Technology Ltd Antibodies specific for tgf-beta
JP2013040160A (ja) 2011-07-01 2013-02-28 Genentech Inc 自己免疫疾患を治療するための抗ｃｄ８３アゴニスト抗体の使用
LT2731677T (lt) 2011-07-11 2018-07-10 Glenmark Pharmaceuticals S.A. Antikūnai, kurie prisiriša prie ox40, ir jų panaudojimas
CN103890008A (zh) 2011-08-17 2014-06-25 霍夫曼-拉罗奇有限公司 在顽固性肿瘤中抑制血管发生
US8822651B2 (en) 2011-08-30 2014-09-02 Theraclone Sciences, Inc. Human rhinovirus (HRV) antibodies
WO2013041687A1 (en) 2011-09-23 2013-03-28 Amgen Research (Munich) Gmbh Bispecific binding molecules for 5t4 and cd3
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
CN112812183A (zh) 2011-11-16 2021-05-18 勃林格殷格翰国际有限公司 抗il-36r抗体
BR112014013205A2 (pt) 2011-12-01 2020-10-27 Protevobio, Inc. proteína de fusão, seu uso e seu método de produção, composição farmacêutica, ácido nucleico, e kit
JP6415326B2 (ja) 2011-12-16 2018-10-31 ブラスケム エス．エー． 改変された微生物およびそれを用いてブタジエンを作製する方法
TR201815709T4 (tr) 2011-12-22 2018-11-21 Hoffmann La Roche İyon değişim membranı kromatografisi.
WO2013091903A1 (en) 2011-12-22 2013-06-27 Novo Nordisk A/S Anti-crac channel antibodies
CA2859303A1 (en) 2011-12-30 2013-07-04 Oxyrane Uk Limited Methods and materials for reducing degradation of recombinant proteins
JP6310398B2 (ja) 2012-01-19 2018-04-11 ユニバーシティ・オブ・シンシナティ 非グリコシル化アポリポタンパク質ａ−ｉｖを用いて糖尿病を処置する方法
WO2013116287A1 (en) 2012-01-31 2013-08-08 Genentech, Inc. Anti-ig-e m1' antibodies and methods using same
JP6407726B2 (ja) 2012-03-01 2018-10-24 アムゲン リサーチ （ミュンヘン） ゲーエムベーハーＡＭＧＥＮ Ｒｅｓｅａｒｃｈ（Ｍｕｎｉｃｈ）ＧｍｂＨ 長寿命ポリペプチド結合分子
EP3628326B1 (de) 2012-03-15 2024-02-28 Oxyrane UK Limited Verfahren und materialien zur behandlung von morbus pompe
WO2013158275A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Cell culture methods to reduce acidic species
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
PT2841087T (pt) 2012-04-27 2017-11-27 Us Health Antagonistas de fator de crescimento endotelial vascular e métodos para utilização dos mesmos
CN109206516A (zh) 2012-05-03 2019-01-15 勃林格殷格翰国际有限公司 抗IL-23p19抗体
WO2013177115A2 (en) 2012-05-21 2013-11-28 Abbvie Inc. Novel purification of human, humanized, or chimeric antibodies using protein a affinity chromatography
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
AU2013295721B2 (en) 2012-07-25 2017-07-20 University Of Cincinnati Method of treating type I diabetes using apolipoprotein AIV
JP6033433B2 (ja) 2012-07-25 2016-11-30 ユニバーシティ・オブ・シンシナティ アポリポタンパク質ａｉｖを用いて高血糖障害を治療する方法
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
CN105377288B (zh) 2012-11-05 2019-11-15 达纳-法伯癌症研究所股份有限公司 Xbp1、cd138和cs1肽的组合物制备药物的用途
PE20151289A1 (es) 2013-01-02 2015-10-05 Glenmark Pharmaceuticals Sa Anticuerpos que se unen al tl1a y sus usos
ES2728936T3 (es) 2013-01-25 2019-10-29 Amgen Inc Anticuerpos dirigidos contra CDH19 para melanoma
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
WO2014136065A2 (en) 2013-03-05 2014-09-12 Oxyrane Uk Limited Production of catalytically active type i sulfatase
US10653779B2 (en) 2013-03-13 2020-05-19 Genentech, Inc. Formulations with reduced oxidation
CN110075293A (zh) 2013-03-13 2019-08-02 霍夫曼-拉罗奇有限公司 氧化降低的配制剂
AR095398A1 (es) 2013-03-13 2015-10-14 Genentech Inc Formulaciones con oxidación reducida
BR112015022210A8 (pt) 2013-03-13 2018-01-23 Genentech Inc formulações de anticorpo
HUE049707T2 (hu) 2013-03-13 2020-11-30 Hoffmann La Roche Csökkent oxidációjú kiszerelések
WO2014142882A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Protein purification using displacement chromatography
WO2014159554A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. Low acidic species compositions and methods for producing the same using displacement chromatography
US20140271633A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Mammalian cell culture performance through surfactant supplementation of feed media
SG11201504260UA (en) 2013-03-14 2015-10-29 Abbvie Inc Low acidic species compositions and methods for producing and using the same
WO2014145098A1 (en) 2013-03-15 2014-09-18 Genentech, Inc. Cell culture compositions with antioxidants and methods for polypeptide production
US9505849B2 (en) 2013-03-15 2016-11-29 Amgen Research (Munich) Gmbh Antibody constructs for influenza M2 and CD3
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res (Munich) Gmbh Moléculas de unión para bcma y cd3
US20140283157A1 (en) 2013-03-15 2014-09-18 Diadexus, Inc. Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
AR095596A1 (es) 2013-03-15 2015-10-28 Amgen Res (Munich) Gmbh Moléculas de unión de cadena única comprendiendo n-terminal abp
PT3611180T (pt) 2013-03-15 2022-03-15 Biomolecular Holdings Llc Imunoglobulina híbrida que contém uma ligação não peptídica
US9441035B2 (en) 2013-03-15 2016-09-13 Genentech, Inc. Cell culture media and methods of antibody production
EP2976362B1 (de) 2013-03-19 2019-10-23 Beijing Shenogen Pharma Group Ltd. Antikörper und verfahren zur behandlung von östrogenrezeptor-assoziierten erkrankungen
RU2015145610A (ru) 2013-03-27 2017-05-04 Дженентек, Инк. Применение биомаркеров для оценки лечения желудочно-кишечных воспалительных расстройств антагонистами бета7 интегрина
MX369022B (es) 2013-05-31 2019-10-25 Genentech Inc Anticuerpos anti-ácido teicoico de la pared celular y conjugados.
EP3004156A1 (de) 2013-06-07 2016-04-13 Novo Nordisk A/S Verfahren zur herstellung von reifen insulinpolypeptiden
AR097648A1 (es) 2013-09-13 2016-04-06 Amgen Inc Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide
SG11201602283UA (en) 2013-09-27 2016-04-28 Genentech Inc Anti-pdl1 antibody formulations
US10203327B2 (en) 2013-11-05 2019-02-12 Novartis Ag Organic compounds
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Il-22二聚体在制备静脉注射药物中的应用
EP3083692B1 (de) 2013-12-17 2020-02-19 F.Hoffmann-La Roche Ag Verfahren zur behandlung von krebs mit pd-1-achsenbindenden antagonisten und taxanen
CA2934028A1 (en) 2013-12-17 2015-06-25 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
WO2015095410A1 (en) 2013-12-17 2015-06-25 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
WO2015102341A1 (ko) 2013-12-30 2015-07-09 재단법인 의약바이오컨버젼스연구단 항 krs 모노클로날 항체 및 이의 용도
WO2015116902A1 (en) 2014-01-31 2015-08-06 Genentech, Inc. G-protein coupled receptors in hedgehog signaling
WO2016039801A1 (en) 2014-01-31 2016-03-17 Boehringer Ingelheim International Gmbh Novel anti-baff antibodies
WO2015120075A2 (en) 2014-02-04 2015-08-13 Genentech, Inc. Mutant smoothened and methods of using the same
SI3701971T1 (sl) 2014-03-14 2023-01-31 Biomolecular Holdings LLC, Spojine, uporabne v pripravi hibridnega imunoglobulina, ki vsebuje nepeptidilno vezavo
EP3122799B8 (de) 2014-03-25 2020-03-11 F.Hoffmann-La Roche Ag Verfahren zur herstellung von poloxamer zur verwendung bei zellkulturmedium
MX2016012282A (es) 2014-03-27 2017-01-06 Genentech Inc Metodos para diagnosticar y tratar enfermedad inflamatoria de intestino.
WO2015153514A1 (en) 2014-03-31 2015-10-08 Genentech, Inc. Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
US8961992B1 (en) 2014-04-02 2015-02-24 Tunitas Therapeutics, Inc. Epsigam fusion protein
WO2015184327A1 (en) 2014-05-30 2015-12-03 Braskem S.A. Modified microorganisms comprising an optimized system for oligosaccharide utilization and methods of using same
US20170183376A1 (en) 2014-06-24 2017-06-29 Insight Biopharmaceuticals Ltd. Methods of purifying antibodies
WO2016004197A1 (en) 2014-07-03 2016-01-07 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using cobalt
US20160185848A1 (en) 2014-07-09 2016-06-30 Abbvie Inc. Methods for modulating the glycosylation profile of recombinant proteins using sugars
EP3708679A1 (de) 2014-07-24 2020-09-16 Boehringer Ingelheim International GmbH In der behandlung von il-23a-assoziierten erkrankungen nützlicher biomarker
AR101669A1 (es) 2014-07-31 2017-01-04 Amgen Res (Munich) Gmbh Constructos de anticuerpos para cdh19 y cd3
WO2016016415A1 (en) 2014-07-31 2016-02-04 Amgen Research (Munich) Gmbh Bispecific single chain antibody construct with enhanced tissue distribution
JP6749312B2 (ja) 2014-07-31 2020-09-02 アムゲン リサーチ （ミュンヘン） ゲーエムベーハーＡＭＧＥＮ Ｒｅｓｅａｒｃｈ（Ｍｕｎｉｃｈ）ＧｍｂＨ 最適化された種間特異的二重特異性単鎖抗体コンストラクト
BR112017004393A2 (pt) 2014-09-15 2018-02-27 Genentech Inc formulações de anticorpo
WO2016059602A2 (en) 2014-10-16 2016-04-21 Glaxo Group Limited Methods of treating cancer and related compositions
WO2016081384A1 (en) 2014-11-17 2016-05-26 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
KR20170086536A (ko) 2014-12-03 2017-07-26 제넨테크, 인크. 항-스타필로코커스 아우레우스 항체 리파마이신 접합체 및 이의 용도
WO2016120764A1 (en) 2015-01-26 2016-08-04 Centre Hospitalier Universitaire Vaudois (Chuv) Aspergillus oryzae prolyl endopeptidases and use thereof in degradation of polypeptides
EA201791734A1 (ru) 2015-02-04 2018-01-31 Бёрингер Ингельхайм Интернациональ Гмбх Способ лечения воспалительных заболеваний
US10330683B2 (en) 2015-02-04 2019-06-25 Genentech, Inc. Mutant smoothened and methods of using the same
AU2016222683A1 (en) 2015-02-26 2017-07-13 Genentech, Inc. Integrin beta7 antagonists and methods of treating crohn's disease
EP3265491A1 (de) 2015-03-03 2018-01-10 Xoma (Us) Llc Behandlung von postprandialer hyperinsulinämie und hyperglykämie nach bariatrischer chirurgie
WO2016144773A1 (en) 2015-03-06 2016-09-15 Abbvie Inc. Arabinosylated glycoproteins
WO2016161410A2 (en) 2015-04-03 2016-10-06 Xoma Technology Ltd. Treatment of cancer using inhibitors of tgf-beta and pd-1
AU2016247921A1 (en) 2015-04-14 2017-08-31 Boehringer Ingelheim International Gmbh Methods of treating diseases
EP4276116A3 (de) 2015-04-17 2024-01-17 Amgen Research (Munich) GmbH Bispezifische antikörperkonstrukte für cdh3 und cd3
WO2016196381A1 (en) 2015-05-29 2016-12-08 Genentech, Inc. Pd-l1 promoter methylation in cancer
MX2017016353A (es) 2015-06-17 2018-05-02 Genentech Inc Metodos para tratar canceres de mama metastasicos o localmente avanzados con antagonistas de union al eje de pd-1 y taxanos.
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI717375B (zh) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
TWI793062B (zh) 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Ｄｌｌ３及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI797060B (zh) 2015-08-04 2023-04-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
CA2993276A1 (en) 2015-08-11 2017-02-16 Yong Zheng Novel anti-pd-1 antibodies
US20190248905A1 (en) 2015-09-07 2019-08-15 Helmholtz Zentrum Muenchen-Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) Novel igfr-like receptor and uses thereof
TWI733695B (zh) 2015-09-18 2021-07-21 德商百靈佳殷格翰國際股份有限公司 治療發炎性疾病之方法
US11040114B2 (en) 2015-12-24 2021-06-22 Oxyrane Uk Limited Human alpha-N-acetylgalactosaminidase polypeptide
EP3397287A1 (de) 2015-12-30 2018-11-07 Genentech, Inc. Formulierungen mit reduziertem abbau von polysorbat
CN108430455A (zh) 2015-12-30 2018-08-21 豪夫迈·罗氏有限公司 色氨酸衍生物用于蛋白质配制剂的用途
EA039859B1 (ru) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
KR20180103084A (ko) 2016-02-03 2018-09-18 암젠 리서치 (뮌헨) 게엠베하 Bcma 및 cd3 이중특이성 t 세포 맞물림 항체 작제물
EP3411404B1 (de) 2016-02-03 2022-11-09 Amgen Research (Munich) GmbH Psma- und cd3-bispezifische t-zellaktivierende antikörperkonstrukte
CA3019952A1 (en) 2016-02-04 2017-08-10 Curis, Inc. Mutant smoothened and methods of using the same
EP3430058A4 (de) 2016-03-15 2019-10-23 Generon (Shanghai) Corporation Ltd. Multispezifische fab-fusionsproteine und verwendungen davon
TW202248213A (zh) 2016-03-15 2022-12-16 日商中外製藥股份有限公司 使用pd-1軸結合拮抗劑和抗gpc3抗體治療癌症的方法
WO2017161976A1 (en) 2016-03-23 2017-09-28 Mabspace Biosciences (Suzhou) Co., Ltd Novel anti-pd-l1 antibodies
EP3443005A1 (de) 2016-04-15 2019-02-20 Boehringer Ingelheim International GmbH Verfahren zur behandlung von entzündlichen krankheiten
CN109328069B (zh) 2016-04-15 2023-09-01 亿一生物医药开发(上海)有限公司 Il-22在治疗坏死性小肠结肠炎中的用途
WO2017207694A1 (en) 2016-06-02 2017-12-07 Kohlmann Angelica Antibodies that bind to human anti-müllerian hormone (amh) and their uses
EP3490600A1 (de) 2016-08-01 2019-06-05 Xoma (Us) Llc Parathormon-rezeptor 1 (pth1r)-antikörper und verwendungen davon
JP7250674B2 (ja) 2016-08-08 2023-04-03 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト がんの治療及び診断方法
KR20190049866A (ko) 2016-09-20 2019-05-09 우시 바이올로직스 아일랜드 리미티드 신규한 항-ｐｃｓｋ９ 항체
CA3038679A1 (en) 2016-09-28 2018-04-05 Xoma (Us) Llc Antibodies that bind interleukin-2 and uses thereof
WO2018071504A2 (en) 2016-10-14 2018-04-19 Boehringer Ingelheim International Gmbh Methods of treating diseases
WO2018075474A1 (en) 2016-10-17 2018-04-26 Medical University Of South Carolina Compositions and methods for treating central nervous system injury
US20190352374A1 (en) 2017-01-30 2019-11-21 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Novel igfr_like 2 receptor and uses thereof
JOP20190189A1 (ar) 2017-02-02 2019-08-01 Amgen Res Munich Gmbh تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
EP4095161A1 (de) 2017-03-15 2022-11-30 Tsinghua University Neuartige anti-trkb-antikörper
WO2018182284A1 (ko) 2017-03-27 2018-10-04 재단법인 의약바이오컨버젼스연구단 세포 외막에 노출되는 라이실-tRNA 합성효소 N-말단 영역에 특이적으로 결합하는 항체
CN110461877A (zh) 2017-03-27 2019-11-15 勃林格殷格翰国际有限公司 抗il-36r抗体联合治疗
EP3615569A1 (de) 2017-04-25 2020-03-04 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Antikörper und verfahren zur diagnose und behandlung von epstein-barr-virus-infektionen
WO2018204907A1 (en) 2017-05-05 2018-11-08 Amgen Inc. Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration
US10793634B2 (en) 2017-06-09 2020-10-06 Boehringer Ingelheim International Gmbh Anti-TrkB antibodies
CN111094334A (zh) 2017-07-19 2020-05-01 美国卫生与公众服务部 用于诊断和治疗乙肝病毒感染的抗体和方法
EP3675897A1 (de) 2017-09-01 2020-07-08 Dana Farber Cancer Institute, Inc. Immunogene peptide spezifisch für bcma und taci-antigene zur behandlung von krebs
US11339221B2 (en) 2017-11-01 2022-05-24 Tufts Medical Center, Inc. Bispecific antibody constructs and methods of use
EP3724229A1 (de) 2017-12-11 2020-10-21 Amgen Inc. Kontinuierliches herstellungsverfahren für bispezifische antikörperprodukte
TW201940518A (zh) 2017-12-29 2019-10-16 美商安進公司 針對ｍｕｃ１７和ｃｄ３之雙特異性抗體構建體
US11401336B2 (en) 2018-02-21 2022-08-02 Celgene Corporation BCMA-binding antibodies and uses thereof
KR102340989B1 (ko) 2018-03-28 2021-12-20 에이비온 주식회사 클라우딘 3의 ecl-2에 특이적으로 결합하는 항체, 이의 단편 및 이들의 용도
WO2019195561A2 (en) 2018-04-06 2019-10-10 BioLegend, Inc. Anti-tetraspanin 33 agents and compositions and methods for making and using the same
WO2019213416A1 (en) 2018-05-02 2019-11-07 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
WO2019246557A1 (en) 2018-06-23 2019-12-26 Genentech, Inc. Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
MX2020013885A (es) 2018-06-29 2021-03-09 Boehringer Ingelheim Int Anticuerpos anti-cd40 para su uso en el tratamiento de enfermedades autoinmunes.
BR112021002130A2 (pt) 2018-08-08 2021-05-04 Genentech, Inc. formulação líquida, artigo de fabricação ou kit e método para reduzir a oxidação de um polipeptídeo
EP4249917A3 (de) 2018-09-21 2023-11-08 F. Hoffmann-La Roche AG Diagnosemethoden für dreifach-negativen brustkrebs
CN113365697A (zh) 2018-09-25 2021-09-07 百进生物科技公司 抗tlr9药剂和组合物及其制备方法和使用方法
WO2020069303A1 (en) 2018-09-28 2020-04-02 Amgen Inc. Antibodies against soluble bcma
JP2022512636A (ja) 2018-10-11 2022-02-07 アムジエン・インコーポレーテツド 二重特異性抗体コンストラクトの下流プロセシング
SG11202103124WA (en) 2018-10-23 2021-04-29 Glycardial Diagnostics S L Antibodies specific for glycosylated apoj and uses thereof
WO2020136232A1 (en) 2018-12-28 2020-07-02 Transgene Sa Immunosuppressive m2 protein
EP3941938A1 (de) 2019-03-06 2022-01-26 Dana-Farber Cancer Institute, Inc. Für das b-zell-reifungsantigen spezifische t-zell-rezeptoren zur behandlung von krebs
KR20220004979A (ko) 2019-03-27 2022-01-12 유엠씨 우트레크트 홀딩 비.브이. 조작된 iga 항체 및 사용 방법
JOP20210300A1 (ar) 2019-05-09 2023-01-30 Boehringer Ingelheim Int أجسام مضادة مضادة لسيما 3أ واستخداماتها في علاج أمراض العين أو البصر
EP3978532A4 (de) 2019-05-24 2023-10-18 Sanyou Biopharmaceuticals Co., Ltd. Neue cldn18.2-bindende moleküle
TW202115112A (zh) 2019-06-27 2021-04-16 德商百靈佳殷格翰國際股份有限公司 抗-angpt2抗體
WO2021038296A2 (en) 2019-08-27 2021-03-04 Tonix Pharma Holdings Limited Modified tff2 polypeptides
MX2022002981A (es) 2019-09-10 2022-04-06 Amgen Inc Metodo de purificacion para polipeptidos de union a antigeno biespecificos con capacidad de union dinamica de captura de proteina l mejorada.
EP4032914A4 (de) 2019-09-20 2023-10-18 Kyungpook National University Industry-Academic Cooperation Foundation Antikörper zum detektieren der acetylierung von cox2-protein und verwendungen davon
TW202126685A (zh) 2019-09-24 2021-07-16 德商百靈佳殷格翰國際股份有限公司 抗nrp1a抗體及其用於治療眼或眼部疾病之用途
CA3156683A1 (en) 2019-11-13 2021-05-20 Amgen Inc. METHOD FOR REDUCING AGGREGATE FORMATION IN DOWNSTREAM PROCESSING OF BI-SPECIFIC ANTIGEN-BINDING MOLECULES
WO2021150824A1 (en) 2020-01-22 2021-07-29 Amgen Research (Munich) Gmbh Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
CN113461817A (zh) 2020-03-31 2021-10-01 苏州泽璟生物制药股份有限公司 一种抗人cd47抗体及其抗原结合片段、制备方法和应用
EP4136211A1 (de) 2020-04-15 2023-02-22 Genentech, Inc. Kupferverlustabschwächung
CN115956087A (zh) 2020-05-26 2023-04-11 勃林格殷格翰国际有限公司 抗-pd-1抗体
MX2022015157A (es) 2020-06-02 2023-01-16 Arcus Biosciences Inc Anticuerpos para tigit.
WO2021257497A1 (en) 2020-06-15 2021-12-23 Sarepta Therapeutis, Inc. Adeno-associated virus antibodies and fragments thereof
KR20230025691A (ko) 2020-06-16 2023-02-22 제넨테크, 인크. 삼중 음성 유방암을 치료하기 위한 방법과 조성물
EP3939999A1 (de) 2020-07-14 2022-01-19 Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Antikörper zur neutralisierung der interleukin-11-rezeptor-alpha-unterheinheit (il11ra) und verwendungen davon
WO2022093641A1 (en) 2020-10-30 2022-05-05 BioLegend, Inc. Anti-nkg2a agents and compositions and methods for making and using the same
WO2022093640A1 (en) 2020-10-30 2022-05-05 BioLegend, Inc. Anti-nkg2c agents and compositions and methods for making and using the same
BR112023008670A2 (pt) 2020-11-06 2024-02-06 Amgen Inc Construtos polipeptídicos ligados à cd3
WO2022096704A1 (en) 2020-11-06 2022-05-12 Amgen Inc. Antigen binding domain with reduced clipping rate
JP2023547662A (ja) 2020-11-06 2023-11-13 アムジェン リサーチ （ミュニック） ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｌｄｎ６及びｃｄ３に選択的に結合するポリペプチド構築物
CN112480248B (zh) 2020-11-24 2023-05-05 三优生物医药(上海)有限公司 与cld18a2特异性结合的分子
US20220281914A1 (en) 2020-12-18 2022-09-08 Kiniksa Pharmaceuticals, Ltd. Protein compositions and methods for producing and using the same
AR125290A1 (es) 2021-04-02 2023-07-05 Amgen Inc Construcciones de unión a mageb2
KR20240000575A (ko) 2021-04-26 2024-01-02 수안주 바이오파마슈티컬 컴퍼니 리미티드 이중특이성 항체약물접합체
AU2022313524A1 (en) 2021-07-23 2024-02-15 Helmholtz Zentrum Muenchen - Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) Igfr-l1 antibodies and uses thereof
WO2023105087A1 (en) 2021-12-10 2023-06-15 Tubulis Gmbh Novel flt3 antibodies and antibody-drug-conjugates based thereon, therapeutic methods and uses thereof in combination with tyrosine kinase inhibitors
EP4238988A1 (de) 2022-03-01 2023-09-06 Consejo Superior De Investigaciones Científicas Antikörper gegen sars-cov-2 und verwendungen davon
WO2023173011A1 (en) 2022-03-09 2023-09-14 Bristol-Myers Squibb Company Transient expression of therapeutic proteins
WO2024032891A1 (en) 2022-08-11 2024-02-15 Vib Vzw Glyco-engineered yeast for therapeutic protein production
WO2024059675A2 (en) 2022-09-14 2024-03-21 Amgen Inc. Bispecific molecule stabilizing composition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2068969B (en) * 1980-02-05 1983-07-27 Upjohn Co Gene expression
JPS58146281A (ja) * 1981-10-19 1983-08-31 Suntory Ltd 酵母細胞の形質転換法
US4617274A (en) * 1981-10-29 1986-10-14 Phillips Petroleum Company Biochemical conversions by yeast fermentation at high cell densities
BR8307525A (pt) * 1982-05-19 1984-08-21 Unilever Nv Expressao de proteinas semelhantes a pretrotaumatina em leveduras kluyveromyces
NO840200L (no) * 1983-01-28 1984-07-30 Cefus Corp Glukoamylase cdna.
US4837148A (en) * 1984-10-30 1989-06-06 Phillips Petroleum Company Autonomous replication sequences for yeast strains of the genus pichia
US4855231A (en) * 1984-10-30 1989-08-08 Phillips Petroleum Company Regulatory region for heterologous gene expression in yeast

Also Published As

Publication number Publication date
IE852473L (en) 1986-04-30
IE58217B1 (en) 1993-08-11
FI94428B (fi) 1995-05-31
US4879231A (en) 1989-11-07
AU572353B2 (en) 1988-05-05
SG43092G (en) 1992-06-12
IL76763A (en) 1991-03-10
ATE68204T1 (de) 1991-10-15
EP0183070A2 (de) 1986-06-04
DK496485A (da) 1986-05-01
NO178975B (no) 1996-04-01
EP0183070B1 (de) 1991-10-09
FI854145A0 (fi) 1985-10-23
DK496485D0 (da) 1985-10-29
CA1297438C (en) 1992-03-17
EP0183070A3 (en) 1987-09-30
ZA858180B (en) 1986-06-25
JPH0681593B2 (ja) 1994-10-19
AU4875685A (en) 1986-06-12
MX430A (es) 1993-11-01
GR852609B (de) 1986-03-04
ES8609464A1 (es) 1986-09-01
IL76763A0 (en) 1986-02-28
PT81402A (en) 1985-11-01
NO178975C (no) 1996-07-10
PT81402B (pt) 1987-11-11
FI854145L (fi) 1986-05-01
FI94428C (fi) 1995-09-11
JPS61108383A (ja) 1986-05-27
ES548306A0 (es) 1986-09-01
NO854334L (no) 1986-05-02

Similar Documents

Publication Publication Date Title
DE3584353D1 (de) Transformation von hefe des genus pichia.
ES8609477A1 (es) Un metodo para aislar material genetico a partir de cepas delevaduras del genero pichia
DE3587168D1 (de) Glucoamylasegen.
ATE54167T1 (de) Promotoren fuer die expression von fremden genen in hefe, plasmide, die diese promotoren enthalten, sowie deren verwendung zur herstellung von polypeptiden.
ES518348A0 (es) Un plasmido vector recombinante.
ES8602116A1 (es) Un procedimiento para hidrolizar almidon con una enzima de alfa-amilasa
ATE81136T1 (de) Immunogenes produkt, erhalten durch expression in einer rekombinanten hefe, und verfahren zu seiner reinigung.
PT81052B (pt) Processo de preparacao de saccharomyces recombinantes
EP0343388A3 (de) Expression von Gamma-Interferon in methylotrophischen Hefen
ATE39117T1 (de) Verfahren und zwischenprodukte fuer sorbinil.
ES8605574A1 (es) Procedimiento para preparar una alcoholdeshidrogenasa

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: RESEARCH CORPORATION TECHNOLOGIES, INC. (N.D.GES.D

8328 Change in the person/name/address of the agent

Free format text: BARDEHLE, H., DIPL.-ING. DOST, W., DIPL.-CHEM. DR.RER.NAT. ALTENBURG, U., DIPL.-PHYS., PAT.-ANWAELTE GEISSLER, B., DIPL.-PHYS.DR.JUR., PAT.- U. RECHTSANW. ROST, J., DIPL.-ING. DOSTERSCHILL, P., DIPL.-ING.DIPL.-WIRTSCH.-ING.DR.RER.POL., 81679 MUENCHEN KAHLHOEFER, H., DIPL.-PHYS., PAT.-ANWAELTE, 40474 DUESSELDORF PAGENBERG, J., DR.JUR. FROHWITTER, B., DIPL.-ING., RECHTSANWAELTE, 81679 MUENCHEN